全文获取类型
收费全文 | 21735篇 |
免费 | 3522篇 |
国内免费 | 369篇 |
专业分类
耳鼻咽喉 | 855篇 |
儿科学 | 357篇 |
妇产科学 | 361篇 |
基础医学 | 2264篇 |
口腔科学 | 637篇 |
临床医学 | 2617篇 |
内科学 | 4305篇 |
皮肤病学 | 974篇 |
神经病学 | 2205篇 |
特种医学 | 1162篇 |
外科学 | 4636篇 |
综合类 | 77篇 |
现状与发展 | 2篇 |
一般理论 | 2篇 |
预防医学 | 1244篇 |
眼科学 | 630篇 |
药学 | 1323篇 |
中国医学 | 152篇 |
肿瘤学 | 1823篇 |
出版年
2024年 | 103篇 |
2023年 | 585篇 |
2022年 | 433篇 |
2021年 | 763篇 |
2020年 | 927篇 |
2019年 | 512篇 |
2018年 | 1009篇 |
2017年 | 898篇 |
2016年 | 1161篇 |
2015年 | 1191篇 |
2014年 | 1591篇 |
2013年 | 1776篇 |
2012年 | 1372篇 |
2011年 | 1244篇 |
2010年 | 1250篇 |
2009年 | 1371篇 |
2008年 | 1054篇 |
2007年 | 921篇 |
2006年 | 933篇 |
2005年 | 723篇 |
2004年 | 563篇 |
2003年 | 478篇 |
2002年 | 406篇 |
2001年 | 391篇 |
2000年 | 294篇 |
1999年 | 299篇 |
1998年 | 311篇 |
1997年 | 315篇 |
1996年 | 348篇 |
1995年 | 313篇 |
1994年 | 198篇 |
1993年 | 145篇 |
1992年 | 161篇 |
1991年 | 161篇 |
1990年 | 99篇 |
1989年 | 147篇 |
1988年 | 114篇 |
1987年 | 93篇 |
1986年 | 94篇 |
1985年 | 94篇 |
1984年 | 96篇 |
1983年 | 72篇 |
1982年 | 78篇 |
1981年 | 53篇 |
1980年 | 54篇 |
1979年 | 36篇 |
1978年 | 50篇 |
1977年 | 50篇 |
1976年 | 36篇 |
1975年 | 43篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Kara S. Tanaka MD Veronica R. Andaya BA Steven W. Thorpe MD Kenneth R. Gundle MD James B. Hayden MD Yee-Cheen Duong MD Raffi S. Avedian MD David G. Mohler MD Lee J. Morse MD Melissa N. Zimel MD Richard J. O'Donnell MD Andrew Fang MD Robert Lor Randall MD Tina H. Tran BS Christin New BA Rosanna L. Wustrack MD other members of Study Group FORCE 《Journal of surgical oncology》2023,127(1):148-158
2.
3.
4.
JeongYun Choi Haeseung Lee EunJi Kwon HyeonJoon Kong OkSeon Kwon HyukJin Cha 《Molecular oncology》2021,15(2):679
The acquisition of chemoresistance remains a major cause of cancer mortality due to the limited accessibility of targeted or immune therapies. However, given that severe alterations of molecular features during epithelial‐to‐mesenchymal transition (EMT) lead to acquired chemoresistance, emerging studies have focused on identifying targetable drivers associated with acquired chemoresistance. Particularly, AXL, a key receptor tyrosine kinase that confers resistance against targets and chemotherapeutics, is highly expressed in mesenchymal cancer cells. However, the underlying mechanism of AXL induction in mesenchymal cancer cells is poorly understood. Our study revealed that the YAP signature, which was highly enriched in mesenchymal‐type lung cancer, was closely correlated to AXL expression in 181 lung cancer cell lines. Moreover, using isogenic lung cancer cell pairs, we also found that doxorubicin treatment induced YAP nuclear translocation in mesenchymal‐type lung cancer cells to induce AXL expression. Additionally, the concurrent activation of TGFβ signaling coordinated YAP‐dependent AXL expression through SMAD4. These data suggest that crosstalk between YAP and the TGFβ/SMAD axis upon treatment with chemotherapeutics might be a promising target to improve chemosensitivity in mesenchymal‐type lung cancer.
Abbreviations
- AUC
- area under the curve
- AXL
- AXL receptor tyrosine kinase
- BCL2
- B‐cell lymphoma 2
- CTD2
- cancer target discovery and development
- CTGF
- connective tissue growth factor
- DEG
- differentially expressed genes
- DOXO
- doxorubicin
- EMT
- epithelial–mesenchymal transition
- Eto
- etoposide
- FDA
- Food and Drug Administration
- ITGB3
- integrin beta‐3
- MAPK
- mitogen‐activated protein kinase
- MMP2
- matrix metalloproteinase‐2
- MMP9
- matrix metalloproteinase‐9
- mRNA
- messenger RNA
- NF‐κB
- nuclear factor kappa‐light‐chain‐enhancer of activated B cells
- SBE
- SMAD binding element
- SERPINE1
- serpin family E member 1
- siRNA
- small interfering RNA
- ssGSEA
- single‐sample gene set enrichment analysis
- TCGA
- The Cancer Genome Atlas
- TGFβ
- transforming growth factor beta
- YAP
- Yes‐associated protein
- YAP8SA
- mutants of inhibitory phosphorylation site at eight serine to Alanine of YAP
- ZEB1
- zinc finger E‐box binding homeobox 1
- ZEB2
- zinc finger E‐box‐binding homeobox 2
5.
6.
7.
Kanghyun Kim Kwantae Noh Janghyun Paek Kung-Rock Kwon Ahran Pae 《The journal of advanced prosthodontics》2015,7(5):406-410
Russell-Silver syndrome (RSS) is a congenital disease characterized by short stature due to growth hormone deficiency, physical asymmetry, inverted triangular face, micrognathia, prominent forehead, and hypodontia. This case report presents a prosthetic management of a 6-year-old patient with Russell-Silver syndrome treated with overdentures on the maxilla and the mandible using the remaining primary teeth. Subsequent and comprehensive dental management considering the growth and development of a young patient will be necessary. 相似文献
8.
9.